Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/s40425-017-0229-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Melanoma-Specific MHC-II Expression Represents a Tumour-Autonomous Phenotype and Predicts Response to Anti-Pd-1/Pd-L1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2016English

Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy

Oncolytic Virotherapy
2018English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

Microsatellite Instability Status Predicts Response to Anti-Pd-1/Pd-L1 Therapy Regardless the Histotype: A Comment on Recent Advances

Bosnian Journal of Basic Medical Sciences
Medicine
2017English

Complete Response to Anti-Pd-1 Antibody Monotherapy in Metastatic Melanoma-Can Therapy Be Discontinued? A Review of Current Literature

Journal of Cancer Biology and Therapeutics
2019English

ADAM10 and ADAM17 Cleave PD-L1 to Mediate PD-(L)1 Inhibitor Resistance

OncoImmunology
OncologyAllergyImmunology
2020English

Reply to ‘Challenging PD-L1 Expressing Cytotoxic T Cells as a Predictor for Response to Immunotherapy in Melanoma’

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

OR12: Expression and Localization of PD‐1 and PD‐L1 in Mouse Testes

American Journal of Reproductive Immunology
GynecologyReproductive MedicineImmunologyObstetricsAllergy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy